4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Progressive Supranuclear Palsy
Explore 13 assets in Progressive Supranuclear Palsy →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Molecular NeuroImaging
Modality
Small molecule
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03058965CT.gov Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Progressive Supranuclear Palsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE (this asset) | Molecular NeuroImaging | Early P1 | CCC · 48 |
| Ioflupane | GE Healthcare | P3 | BB |
| Zoledronate | California Pacific Medical Center Research Institute | P4 | BB |
| Riluzole | King's College London | P3 | B |
| [18F]MNI-958 | Invicro | P1 | B |
| Droxidopa | Loma Linda University | P2 | CCC |
| Aadvac1 | Adam Boxer | P2 | CCC |
| Lithium, Elemental | Westat | P1/2 | CCC |
| Davunetide | University of California, San Francisco | P1 | CC |
+16 more in the Progressive Supranuclear Palsy cohort
Other indications for 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P4 | BBB · 78 |
| Cognitive Disorder | — | P2/3 | BB · 66 |
| Multiple Sclerosis | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE in Progressive Supranuclear Palsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/4-1e-2-6-2-2-2-fluoroethoxyethoxyethoxypyridin-3-ylethenyl-n-methylbenzenamine-progressive-supranuclear-palsy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →